Valentin Fuhrmann

Valentin Fuhrmann

Auto-generated profile, based on publicly available information

Valentin Fuhrmann

Universitätsklinikum Hamburg-Eppendorf, Klinik für Intensivmedizin, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2020 in Critical Care
Verified
Journal Article
Open access
PDF file
ABAnnika Reintam Blaser
Annika Reintam Blaser
Jean Charles PreiserJean Charles Preiser
Jean Charles Preiser
SFSonja Fruhwald
Sonja Fruhwald
AWAlexander Wilmer
Alexander Wilmer
JWJan Wernerman
Jan Wernerman
ADAdam M. Deane
Adam M. Deane
Background: Gastrointestinal (GI) dysfunction is frequent in the critically ill but can be overlooked as a result of the lack of standardization of the diagnostic and therapeutic approaches. We aimed to develop a research agenda for GI dysfunction for future research. We systematically reviewed the current knowledge on a broad range of subtopics from a specific viewpoint of GI dysfunction, highlighting the remaining areas of uncertainty and suggesting future studies. Methods: This systematic scoping review and research agenda was conducted following successive steps: (1) identify clinically important subtopics within the field of GI function which warrant further research; (2) systematically review the literature for each subtopic using PubMed, CENTRAL and Cochrane Database of Systematic Reviews; (3) summarize evidence for each subtopic; (4) identify areas of uncertainty; (5) formulate and refine study proposals that address these subtopics; and (6) prioritize study proposals via sequential voting rounds. Results: Five major themes were identified: (1) monitoring, (2) associations between GI function and outcome, (3) GI function and nutrition, (4) management of GI dysfunction and (5) pathophysiological mechanisms. Searches on 17 subtopics were performed and evidence summarized. Several areas of uncertainty were identified, six of them needing consensus process. Study proposals ranked among the first ten included: prevention and management of diarrhoea; management of upper and lower feeding intolerance, including indications for post-pyloric feeding and opioid antagonists; acute gastrointestinal injury grading as a bedside tool; the role of intra-abdominal hypertension in the development and monitoring of GI dysfunction and in the development of non-occlusive mesenteric ischaemia; and the effect of proton pump inhibitors on the microbiome in critical illness. Conclusions: Current evidence on GI dysfunction is scarce, partially due to the lack of precise definitions. The use of core sets of monitoring and outcomes are required to improve the consistency of future studies. We propose several areas for consensus process and outline future study projects.

19 June 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
THThomas Horvatits
Thomas Horvatits
ADAndreas Drolz
Andreas Drolz
MTMichael Trauner
Michael Trauner
VFValentin Fuhrmann
Valentin Fuhrmann

1 April 2019 in Resuscitation
Verified
Journal Article
Closed access
KRKevin Roedl
Kevin Roedl
Alexander SpielAlexander Spiel
Alexander Spiel
ANAlexander Nürnberger
Alexander Nürnberger
THThomas Horvatits
Thomas Horvatits
ADAndreas Drolz
Andreas Drolz
VFValentin Fuhrmann
Valentin Fuhrmann

1 October 2017 in The American Journal of Cardiology
Verified
Journal Article
Open access
TJToni Jäntti
Toni Jäntti
TTTuukka Tarvasmäki
Tuukka Tarvasmäki
VHVeli-Pekka Harjola
Veli-Pekka Harjola
John ParissisJohn Parissis
John Parissis
KPKari Pulkki
Kari Pulkki
PGPiotr Góral
Piotr Góral
Cardiogenic shock (CS) is a cardiac emergency often leading to multiple organ failure and death. Assessing organ dysfunction and appropriate risk stratification are central for the optimal management of these patients. The purpose of this study was to assess the prevalence of abnormal liver function tests (LFTs), as well as early changes of LFTs and their impact on outcome in CS. We measured LFTs in 178 patients in CS from serial blood samples taken at 0 hours, 12 hours, and 24 hours. The associations of LFT abnormalities and their early changes with all-cause 90-day mortality were estimated using Fisher's exact test and Cox proportional hazards regression analysis. Baseline alanine aminotransferase (ALT) was abnormal in 58% of the patients, more frequently in nonsurvivors. Abnormalities in other LFTs analyzed (alkaline phosphatase, gamma-glutamyl transferase, and total bilirubin) were not associated with short-term mortality. An increase in ALT of >20% within 24 hours (ΔALT>+20%) was observed in 24% of patients. ΔALT>+20% was associated with a more than 2-fold increase in mortality compared with those with stable or decreasing ALT (70% and 28%, p +20% was associated with increased 90-day mortality independent of other known risk factors. In conclusion, an increase in ALT in the initial phase was seen in 1/4 of patients in CS and was independently associated with 90-day mortality. This finding suggests that serial ALT measurements should be incorporated in the clinical assessment of patients in CS.

1 September 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
VFValentin Fuhrmann
Valentin Fuhrmann
MKMichael Krowka
Michael Krowka

1 November 2020 in Resuscitation
Verified
Journal Article
Closed access
KRKevin Roedl
Kevin Roedl
DJDominik Jarczak
Dominik Jarczak
RBRasmus Blohm
Rasmus Blohm
SWSarah Winterland
Sarah Winterland
JMJakob Müller
Jakob Müller
SKStefan Kluge
Stefan Kluge